VYEPTI (eptinezumab-jjmr) Intravenous Drug as a Preventive Treatment of Migraine

JOURNAL TITLE: Pondicherry Journal of Nursing

Author
1. Mani Vijayanandh
ISSN
2279-0144
DOI
10.5005/jp-journals-10084-12118
Volume
12
Issue
2
Publishing Year
2019
Pages
2
Author Affiliations
    1. Department of Medical Surgical Nursing, Kasturba Gandhi Nursing College, Sri Balaji Vidyapeeth Deemed University, Puducherry, India; Department of Nursing, Sri Balaji Vidyapeeth Deemed University, Puducherry, India
  • Article keywords
    Calcitonin gene-related peptide, Migraine, Monoclonal antibody, VYEPTI

    Abstract

    Migraine occurs due to vasodilation of enzyme named calcitonin gene-related peptide (CGRP), and it binds to the receptors causing vasodilation. VYEPTI is a new intravenous drug for migraine and can be used as a preventive treatment. It is a monoclonal antibody that blocks CGRP binding to the receptor, and hence stopping vasodilation. Individuals with migraine will have to take this injection once in 3 months.

    © 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved